All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

paricalcitol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
Vitamin D analogues/derivatives	2066	131918-61-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: zemplar paricalcitol-d6 paricalcitol	suppressed immunoglobulin production & thymic lymphocyte proliferation in vivo Molecular weight: 416.65 Formula: C27H44O3 CLOGP: 5.69 LIPINSKI: 1 HAC: 3 HDO: 3 TPSA: 60.69 ALOGS: -4.79 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
2	mcg	O
2	mcg	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.00 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	72 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.41 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.89 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.00 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	5.30 hours	Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	ACVR2B,BRAF,CAMK2D,CDK5,EIF2AK3,ERBB2,GRK2,ITK,MAPK7,NTRK2,PDK1,PDK2,PDK4,PRKDC,TEK	15
kinase-selectivity-class	PDK2	1
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

Date	Agency	Company	Orphan
April 17, 1998	FDA	ABBVIE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Death	3386.28	25.31	1262	5826	455289	90166070
Cardiac disorder	500.20	25.31	182	6906	56690	90564669
Infarction	346.33	25.31	73	7015	2940	90618419
Sepsis	261.96	25.31	167	6921	179647	90441712
Myocardial infarction	193.92	25.31	114	6974	105858	90515501
Cardio-respiratory arrest	179.63	25.31	91	6997	63049	90558310
Cardiac failure	172.46	25.31	107	6981	109389	90511970
Calciphylaxis	161.20	25.31	40	7048	3336	90618023
Cardiovascular disorder	159.76	25.31	54	7034	13438	90607921
Respiratory arrest	153.46	25.31	67	7021	33244	90588115
Nephrogenic systemic fibrosis	134.29	25.31	36	7052	4072	90617287
Adverse event	127.37	25.31	91	6997	117327	90504032
Cerebrovascular disorder	93.65	25.31	25	7063	2781	90618578
Blood parathyroid hormone increased	88.63	25.31	25	7063	3412	90617947
Skin induration	85.35	25.31	24	7064	3238	90618121
Acute myocardial infarction	83.98	25.31	45	7043	34845	90586514
Renal transplant	75.57	25.31	19	7069	1669	90619690
Skin hypertrophy	69.81	25.31	21	7067	3589	90617770
Skin tightness	69.42	25.31	22	7066	4466	90616893
Chronic kidney disease	68.81	25.31	45	7043	50146	90571213
Cerebrovascular accident	64.99	25.31	63	7025	123470	90497889
Peritonitis bacterial	58.45	25.31	20	7068	5151	90616208
Cardiac arrest	48.68	25.31	50	7038	104885	90516474
Peritoneal dialysis complication	45.34	25.31	12	7076	1290	90620069
Skin fibrosis	44.79	25.31	11	7077	877	90620482
Hyperphosphataemia	44.48	25.31	15	7073	3696	90617663
Blood parathyroid hormone abnormal	40.01	25.31	8	7080	246	90621113
Device related infection	39.99	25.31	25	7063	25761	90595598
Arteriovenous fistula thrombosis	39.73	25.31	8	7080	255	90621104
Transplant	38.12	25.31	10	7078	1039	90620320
Drug ineffective	37.68	25.31	32	7056	1384266	89237093
Parathyroidectomy	37.50	25.31	8	7080	340	90621019
Haemorrhagic stroke	36.30	25.31	15	7073	6481	90614878
Shunt occlusion	36.07	25.31	9	7079	766	90620593
Off label use	35.85	25.31	21	7067	1102231	89519128
Acute pulmonary oedema	33.75	25.31	16	7072	9564	90611795
Hypercalcaemia	33.56	25.31	25	7063	34215	90587144
Device related sepsis	33.49	25.31	13	7075	4780	90616579
Joint contracture	33.22	25.31	10	7078	1712	90619647
Azotaemia	32.11	25.31	13	7075	5335	90616024
Pemphigoid	31.57	25.31	15	7073	9011	90612348
Fibrosis	30.76	25.31	13	7075	5939	90615420
Osteomalacia	29.98	25.31	8	7080	887	90620472
Sudden death	28.87	25.31	15	7073	10894	90610465
Unevaluable event	28.86	25.31	28	7060	54820	90566539
Arteriovenous fistula operation	28.26	25.31	6	7082	249	90621110
Pulmonary sepsis	26.67	25.31	9	7079	2222	90619137
Sudden cardiac death	26.66	25.31	9	7079	2223	90619136

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Death	3930.94	27.17	1859	6868	469326	42143282
Cardiac disorder	724.40	27.17	297	8430	48635	42563973
Infarction	497.24	27.17	117	8610	2918	42609690
Myocardial infarction	347.77	27.17	249	8478	123760	42488848
Cardiovascular disorder	227.55	27.17	90	8637	13275	42599333
Adverse event	208.18	27.17	100	8627	23540	42589068
Sepsis	178.13	27.17	211	8516	199123	42413485
Cardiac failure	167.44	27.17	153	8574	106703	42505905
Respiratory arrest	162.69	27.17	90	8637	28334	42584274
Cardio-respiratory arrest	152.94	27.17	113	8614	58523	42554085
Transplant	131.41	27.17	32	8695	922	42611686
Calciphylaxis	129.76	27.17	33	8694	1140	42611468
Renal transplant	118.78	27.17	36	8691	2389	42610219
Cerebrovascular accident	103.67	27.17	113	8614	97047	42515561
Cerebrovascular disorder	97.06	27.17	29	8698	1832	42610776
Nephrogenic systemic fibrosis	79.07	27.17	29	8698	3472	42609136
Infection	74.98	27.17	103	8624	111965	42500643
Shunt thrombosis	74.66	27.17	13	8714	62	42612546
Cardiac arrest	72.41	27.17	100	8627	109220	42503388
Parathyroidectomy	71.19	27.17	13	8714	85	42612523
Off label use	66.69	27.17	24	8703	638311	41974297
Skin induration	62.88	27.17	21	8706	1906	42610702
Unevaluable event	59.26	27.17	52	8675	34236	42578372
Acute myocardial infarction	54.00	27.17	63	8664	58102	42554506
Shunt occlusion	53.54	27.17	16	8711	1011	42611597
Blood parathyroid hormone increased	51.18	27.17	18	8709	1909	42610699
Drug ineffective	47.58	27.17	36	8691	630161	41982447
Skin hypertrophy	41.28	27.17	17	8710	2772	42609836
Chronic kidney disease	38.65	27.17	48	8679	47193	42565415
Skin tightness	37.98	27.17	15	8712	2195	42610413
Peritoneal dialysis complication	32.84	27.17	13	8714	1914	42610694
Peritonitis bacterial	29.20	27.17	18	8709	6897	42605711
Sudden death	28.27	27.17	25	8702	16604	42596004
Haemorrhagic stroke	28.07	27.17	18	8709	7384	42605224
Joint range of motion decreased	27.31	27.17	18	8709	7735	42604873
Angiosclerosis	27.21	27.17	4	8723	4	42612604

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Myocardial infarction	419.16	22.41	231	8374	191852	110388842
Death	386.14	22.41	363	8242	698506	109882188
Cardio-respiratory arrest	325.13	22.41	165	8440	115671	110465023
Cardiac disorder	268.83	22.41	127	8478	76153	110504541
Calciphylaxis	263.96	22.41	62	8543	4125	110576569
Infarction	215.03	22.41	55	8550	5214	110575480
Sepsis	212.80	22.41	187	8418	327159	110253535
Respiratory arrest	186.86	22.41	91	8514	58208	110522486
Nephrogenic systemic fibrosis	179.26	22.41	48	8557	5435	110575259
Cardiac failure	174.05	22.41	132	8473	187494	110393200
Skin induration	136.73	22.41	37	8568	4358	110576336
Acute myocardial infarction	117.46	22.41	76	8529	83701	110496993
Skin hypertrophy	104.88	22.41	31	8574	5016	110575678
Renal transplant	99.50	22.41	27	8578	3211	110577483
Skin tightness	93.16	22.41	29	8576	5584	110575110
Peritonitis bacterial	86.15	22.41	32	8573	10501	110570193
Blood parathyroid hormone increased	83.51	22.41	25	8580	4223	110576471
Peritoneal dialysis complication	81.85	22.41	22	8583	2524	110578170
Chronic kidney disease	78.02	22.41	57	8548	76234	110504460
Parathyroidectomy	75.92	22.41	14	8591	279	110580415
Cardiac arrest	74.58	22.41	84	8521	196669	110384025
Cerebrovascular disorder	65.07	22.41	20	8585	3691	110577003
Skin fibrosis	63.96	22.41	16	8589	1384	110579310
Shunt thrombosis	56.72	22.41	10	8595	153	110580541
Cardiovascular disorder	56.71	22.41	30	8575	22730	110557964
Shunt occlusion	55.79	22.41	15	8590	1722	110578972
Joint contracture	50.44	22.41	15	8590	2476	110578218
Peritonitis	49.18	22.41	31	8574	32576	110548118
Azotaemia	48.84	22.41	21	8584	10064	110570630
Scar	44.19	22.41	23	8582	16858	110563836
Cerebrovascular accident	44.03	22.41	62	8543	181222	110399472
Arteriovenous fistula thrombosis	43.67	22.41	10	8595	593	110580101
Device related infection	41.45	22.41	30	8575	39489	110541205
Hypercalcaemia	41.32	22.41	32	8573	46625	110534069
Transplant	40.91	22.41	11	8594	1263	110579431
Fibrosis	40.61	22.41	17	8588	7625	110573069
Device related sepsis	37.28	22.41	16	8589	7631	110573063
Blood parathyroid hormone abnormal	36.51	22.41	8	8597	388	110580306
Off label use	34.24	22.41	40	8565	1500145	109080549
Osteomalacia	34.07	22.41	10	8595	1577	110579117
Sudden death	33.83	22.41	22	8583	24373	110556321
Cardiopulmonary failure	33.54	22.41	15	8590	7888	110572806
Parathyroid tumour benign	33.28	22.41	9	8596	1056	110579638
Skin hyperpigmentation	32.17	22.41	15	8590	8681	110572013
Arrhythmia	30.31	22.41	32	8573	69543	110511151
Hypertensive crisis	29.03	22.41	20	8585	24352	110556342
Nephropathy	28.67	22.41	16	8589	13451	110567243
Hypocalcaemia	28.36	22.41	30	8575	65336	110515358
Haemorrhagic stroke	28.32	22.41	16	8589	13773	110566921
Dialysis	27.96	22.41	18	8587	19601	110561093
Coronary artery disease	27.78	22.41	31	8574	71659	110509035
Arteriovenous fistula operation	26.17	22.41	6	8599	358	110580336
Shunt malfunction	26.07	22.41	6	8599	364	110580330
Hyperparathyroidism	25.49	22.41	10	8595	3800	110576894
Extremity contracture	24.68	22.41	8	8597	1753	110578941
Drug ineffective	23.82	22.41	52	8553	1520488	109060206
Hypotonia	23.81	22.41	15	8590	15730	110564964
Urosepsis	22.82	22.41	19	8586	30656	110550038
Acute pulmonary oedema	22.76	22.41	15	8590	16981	110563713
Peripheral arterial occlusive disease	22.46	22.41	12	8593	9268	110571426

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	H05BX02	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS CALCIUM HOMEOSTASIS ANTI-PARATHYROID AGENTS Other anti-parathyroid agents
FDA CS	M0007651	Ergocalciferols
FDA EPC	N0000175849	Vitamin D Analog
FDA EPC	N0000175907	Vitamin D2 Analog
CHEBI has role	CHEBI:35526	hypoglycemic agent
CHEBI has role	CHEBI:35610	antineoplastic agent
CHEBI has role	CHEBI:50827	antiparathyroid drug
CHEBI has role	CHEBI:76595	nephroprotective agent
CHEBI has role	CHEBI:231911	renoprotective agent

Related Drugs by ATC class:

H05BX Other anti-parathyroid agents 5 drugs

calcifediolcinacalcetdoxercalciferoletelcalcetideevocalcet

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hyperparathyroidism Secondary to Chronic Renal Failure	indication
Poisoning by digitalis glycoside	contraindication	12876009
Hyperphosphatemia	contraindication	20165001	DOID:0050459
Hypervitaminosis D	contraindication	27712000	DOID:9971
Hypercalcemia	contraindication	66931009	DOID:12678

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Vitamin D3 receptor	Nuclear hormone receptor	P11473	VDR_HUMAN	AGONIST	EC50	8.70		WOMBAT-PK	CHEMBL

External reference:

ID	Source
4021107	VUID
N0000148562	NUI
D00930	KEGG_DRUG
4021107	VANDF
C0249582	UMLSCUI
CHEBI:7931	CHEBI
CHEMBL1200622	ChEMBL_ID
DB00910	DRUGBANK_ID
C084656	MESH_SUPPLEMENTAL_RECORD_UI
5281104	PUBCHEM_CID
2791	IUPHAR_LIGAND_ID
7688	INN_ID
6702D36OG5	UNII
221005	RXNORM
11702	MMSL
206206	MMSL
5234	MMSL
d04312	MMSL
007498	NDDF
108946001	SNOMEDCT_US
126233000	SNOMEDCT_US
6702D36OG5	INXIGHT DRUGS

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Zemplar	HUMAN PRESCRIPTION DRUG LABEL	1	0074-1658	INJECTION, SOLUTION	5 ug	INTRAVENOUS	NDA	27 sections
Zemplar	HUMAN PRESCRIPTION DRUG LABEL	1	0074-4314	CAPSULE, LIQUID FILLED	2 ug	ORAL	NDA	28 sections
Zemplar	HUMAN PRESCRIPTION DRUG LABEL	1	0074-4317	CAPSULE, LIQUID FILLED	1 ug	ORAL	NDA	28 sections
Zemplar	HUMAN PRESCRIPTION DRUG LABEL	1	0074-4637	INJECTION, SOLUTION	2 ug	INTRAVENOUS	NDA	27 sections
Zemplar	HUMAN PRESCRIPTION DRUG LABEL	1	0074-9036	CAPSULE, LIQUID FILLED	1 ug	ORAL	NDA	28 sections
Zemplar	HUMAN PRESCRIPTION DRUG LABEL	1	0074-9037	CAPSULE, LIQUID FILLED	2 ug	ORAL	NDA	28 sections
Paricalcitol	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9596	INJECTION	5 ug	INTRAVENOUS	NDA	24 sections
Paricalcitol	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9624	INJECTION	5 ug	INTRAVENOUS	NDA	24 sections
Paricalcitol	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9625	INJECTION	2 ug	INTRAVENOUS	NDA	24 sections
Paricalcitol	HUMAN PRESCRIPTION DRUG LABEL	1	10888-5001	CAPSULE, LIQUID FILLED	1 ug	ORAL	ANDA	26 sections
Paricalcitol	HUMAN PRESCRIPTION DRUG LABEL	1	10888-5002	CAPSULE, LIQUID FILLED	2 ug	ORAL	ANDA	26 sections
Paricalcitol	HUMAN PRESCRIPTION DRUG LABEL	1	10888-5003	CAPSULE, LIQUID FILLED	4 ug	ORAL	ANDA	26 sections
Paricalcitol	HUMAN PRESCRIPTION DRUG LABEL	1	16729-310	INJECTION, SOLUTION	2 ug	INTRAVENOUS	NDA	24 sections
Paricalcitol	HUMAN PRESCRIPTION DRUG LABEL	1	16729-311	INJECTION, SOLUTION	5 ug	INTRAVENOUS	NDA	24 sections
Paricalcitol	Human Prescription Drug Label	1	25000-012	CAPSULE, LIQUID FILLED	1 ug	ORAL	ANDA	24 sections
Paricalcitol	Human Prescription Drug Label	1	25000-014	CAPSULE, LIQUID FILLED	2 ug	ORAL	ANDA	24 sections
Paricalcitol	Human Prescription Drug Label	1	25000-017	CAPSULE, LIQUID FILLED	4 ug	ORAL	ANDA	24 sections
Paricalcitol	HUMAN PRESCRIPTION DRUG LABEL	1	49483-687	CAPSULE, LIQUID FILLED	1 ug	ORAL	ANDA	24 sections
Paricalcitol	HUMAN PRESCRIPTION DRUG LABEL	1	49483-688	CAPSULE, LIQUID FILLED	2 ug	ORAL	ANDA	24 sections
Paricalcitol	HUMAN PRESCRIPTION DRUG LABEL	1	49483-689	CAPSULE, LIQUID FILLED	4 ug	ORAL	ANDA	24 sections
Paricalcitol	HUMAN PRESCRIPTION DRUG LABEL	1	55111-663	CAPSULE, LIQUID FILLED	1 ug	ORAL	ANDA	25 sections
Paricalcitol	HUMAN PRESCRIPTION DRUG LABEL	1	55111-664	CAPSULE, LIQUID FILLED	2 ug	ORAL	ANDA	25 sections
Paricalcitol	HUMAN PRESCRIPTION DRUG LABEL	1	55111-665	CAPSULE, LIQUID FILLED	4 ug	ORAL	ANDA	25 sections
PARICALCITOL	Human Prescription Drug Label	1	55150-212	INJECTION	2 ug	INTRAVENOUS	ANDA	24 sections
PARICALCITOL	Human Prescription Drug Label	1	55150-212	INJECTION	2 ug	INTRAVENOUS	ANDA	24 sections
PARICALCITOL	Human Prescription Drug Label	1	55150-213	INJECTION	5 ug	INTRAVENOUS	ANDA	24 sections
PARICALCITOL	Human Prescription Drug Label	1	55150-213	INJECTION	5 ug	INTRAVENOUS	ANDA	24 sections
PARICALCITOL	Human Prescription Drug Label	1	55150-214	INJECTION	10 ug	INTRAVENOUS	ANDA	24 sections
PARICALCITOL	Human Prescription Drug Label	1	55150-214	INJECTION	10 ug	INTRAVENOUS	ANDA	24 sections
PARICALCITOL	Human Prescription Drug Label	1	55150-215	INJECTION	10 ug	INTRAVENOUS	ANDA	24 sections